275 related articles for article (PubMed ID: 26670554)
1. Empagliflozin/metformin (Synjardy) for type 2 diabetes.
Med Lett Drugs Ther; 2015 Dec; 57(1484):172-4. PubMed ID: 26670554
[No Abstract] [Full Text] [Related]
2. Dapagliflozin/saxagliptin (Qtern) for type 2 diabetes.
Med Lett Drugs Ther; 2018 Mar; 60(1543):55-56. PubMed ID: 29635266
[No Abstract] [Full Text] [Related]
3. Dapagliflozine (Farxiga) for type 2 diabetes.
Med Lett Drugs Ther; 2014 Feb; 56(1436):13-5. PubMed ID: 24663030
[No Abstract] [Full Text] [Related]
4. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia.
Rosenstock J; Seman LJ; Jelaska A; Hantel S; Pinnetti S; Hach T; Woerle HJ
Diabetes Obes Metab; 2013 Dec; 15(12):1154-60. PubMed ID: 23906374
[TBL] [Abstract][Full Text] [Related]
5. SGLT-2 inhibitors as second-line therapy in type 2 diabetes.
Tahrani AA
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):678-9. PubMed ID: 24948512
[No Abstract] [Full Text] [Related]
6. Cost-effectiveness analysis of dapagliflozin treatment versus metformin treatment in Chinese population with type 2 diabetes.
Cai X; Shi L; Yang W; Gu S; Chen Y; Nie L; Ji L
J Med Econ; 2019 Apr; 22(4):336-343. PubMed ID: 30663458
[TBL] [Abstract][Full Text] [Related]
7. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M; Andersen KR; Zeller C; Kim G; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 Sep; 2(9):691-700. PubMed ID: 24948511
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
[TBL] [Abstract][Full Text] [Related]
9. Empagliflozin/metformin fixed-dose combination: a review in patients with type 2 diabetes.
Hu J; Zou P; Zhang S; Zhou M; Tan X
Expert Opin Pharmacother; 2016 Dec; 17(18):2471-2477. PubMed ID: 27819159
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes.
Haering HU; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Meinicke T; Woerle HJ; Broedl UC;
Diabetes Res Clin Pract; 2015 Oct; 110(1):82-90. PubMed ID: 26324220
[TBL] [Abstract][Full Text] [Related]
11. A Phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes.
Ferrannini E; Seman L; Seewaldt-Becker E; Hantel S; Pinnetti S; Woerle HJ
Diabetes Obes Metab; 2013 Aug; 15(8):721-8. PubMed ID: 23398530
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the efficacy and safety of empagliflozin addition to insulin and oral antidiabetic medication (OAD) regimen in poorly controlled type 2 diabetes and obese patients.
Sharif H; Sheikh SS; Salman A; Jawed Z; Karim I; Sohail T; Mohsin N
Pak J Pharm Sci; 2024 Mar; 37(2):357-366. PubMed ID: 38767103
[TBL] [Abstract][Full Text] [Related]
13. The safety of empagliflozin plus metformin for the treatment of type 2 diabetes.
Scheen AJ
Expert Opin Drug Saf; 2018 Aug; 17(8):837-848. PubMed ID: 30068236
[TBL] [Abstract][Full Text] [Related]
14. Ertugliflozin for type 2 diabetes.
Med Lett Drugs Ther; 2018 Apr; 60(1545):70-72. PubMed ID: 29667948
[No Abstract] [Full Text] [Related]
15. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of dapagliflozin monotherapy in people with Type 2 diabetes: a randomized double-blind placebo-controlled 102-week trial.
Bailey CJ; Morales Villegas EC; Woo V; Tang W; Ptaszynska A; List JF
Diabet Med; 2015 Apr; 32(4):531-41. PubMed ID: 25381876
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of dapagliflozin (Forxiga®) added to metformin compared with sulfonylurea added to metformin in type 2 diabetes in the Nordic countries.
Sabale U; Ekman M; Granström O; Bergenheim K; McEwan P
Prim Care Diabetes; 2015 Feb; 9(1):39-47. PubMed ID: 24840612
[TBL] [Abstract][Full Text] [Related]
18. Comparison of the efficacy and safety of 10-mg empagliflozin every day versus every other day in Japanese patients with Type 2 Diabetes Mellitus: a pilot trial.
Obata F; Tani K; Yamaguchi H; Tabata R; Bando H; Imoto I
J Med Invest; 2017; 64(1.2):50-57. PubMed ID: 28373628
[TBL] [Abstract][Full Text] [Related]
19. Ketonuria/ketonemia associated with the use of sodium-glucose cotransporter 2 (SGLT-2) inhibitors in type 2 diabetes: A report of three cases from New Delhi, India.
Ghosh A; Gupta R; Misra A
J Diabetes; 2016 Sep; 8(5):738-9. PubMed ID: 27085074
[No Abstract] [Full Text] [Related]
20. Efficacy and safety of triple therapy with dapagliflozin add-on to saxagliptin plus metformin over 52 weeks in patients with type 2 diabetes.
Mathieu C; Herrera Marmolejo M; González González JG; Hansen L; Chen H; Johnsson E; Garcia-Sanchez R; Iqbal N
Diabetes Obes Metab; 2016 Nov; 18(11):1134-1137. PubMed ID: 27385192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
